Burden of pneumococcal community-acquired pneumonia in adults across Europe: A literature review

Antoni Torres; Catia Cillóniz; Francesco Blasi; James D. Chalmers; Jacques Gaillat; Nathalie Dartois; Heinz-Josef Schmitt; Tobias Welte

doi:10.1016/j.rmed.2018.02.007

Burden of pneumococcal community-acquired pneumonia in adults across Europe: A literature review

Antoni Torres (Lead / Corresponding author), Catia Cillóniz, Francesco Blasi, James D. Chalmers, Jacques Gaillat, Nathalie Dartois, Heinz-Josef Schmitt, Tobias Welte

Research output: Contribution to journal › Review article › peer-review

93 Citations (Scopus)

Abstract

BACKGROUND: The burden of community-acquired pneumonia (CAP) caused by Streptococcus pneumoniae (pneumococcus) among adults in Europe is poorly defined.

METHODS: Structured searches of PubMed were conducted to identify the incidence of pneumococcal CAP among adults across Europe.

RESULTS: The overall incidence rates for CAP was 68-7000 per 100,000 and the incidence in hospitalised CAP cases of all causes was 16-3581 per 100,000. In general the incidence of CAP increased consistently with age. Available data indicated higher burdens of pneumococcal CAP caused in groups with more comorbidities. Most cases of pneumococcal CAP (30%-78%) were caused by serotypes covered by PCV13 vaccine; the incidence of PCV13-related pneumonia decreased after the introduction of childhood vaccination.

CONCLUSIONS: We observed a high burden adult pneumococcal CAP in Europe despite use of the 23-valent pneumococcal polysaccharide vaccine, particularly in elderly patients with comorbidities. CAP surveillance presented wide variations across Europe. Pneumococcal CAP has to be monitored very carefully due to the possible effect of current vaccination strategies.

Original language	English
Pages (from-to)	6-13
Number of pages	8
Journal	Respiratory Medicine
Volume	137
Early online date	19 Feb 2018
DOIs	https://doi.org/10.1016/j.rmed.2018.02.007
Publication status	Published - Apr 2018

Keywords

Community-acquired pneumonia
Epidemiology
Europe
Incidence
Pneumococcal
Pneumococcal vaccines
Pneumonia
Streptococcus pneumoniae

ASJC Scopus subject areas

Pulmonary and Respiratory Medicine

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.rmed.2018.02.007Licence: Elsevier User Licence

Cite this

@article{4c385b9a85114a019ba432f258454d00,

title = "Burden of pneumococcal community-acquired pneumonia in adults across Europe: A literature review",

abstract = "BACKGROUND: The burden of community-acquired pneumonia (CAP) caused by Streptococcus pneumoniae (pneumococcus) among adults in Europe is poorly defined.METHODS: Structured searches of PubMed were conducted to identify the incidence of pneumococcal CAP among adults across Europe.RESULTS: The overall incidence rates for CAP was 68-7000 per 100,000 and the incidence in hospitalised CAP cases of all causes was 16-3581 per 100,000. In general the incidence of CAP increased consistently with age. Available data indicated higher burdens of pneumococcal CAP caused in groups with more comorbidities. Most cases of pneumococcal CAP (30%-78%) were caused by serotypes covered by PCV13 vaccine; the incidence of PCV13-related pneumonia decreased after the introduction of childhood vaccination.CONCLUSIONS: We observed a high burden adult pneumococcal CAP in Europe despite use of the 23-valent pneumococcal polysaccharide vaccine, particularly in elderly patients with comorbidities. CAP surveillance presented wide variations across Europe. Pneumococcal CAP has to be monitored very carefully due to the possible effect of current vaccination strategies.",

keywords = "Community-acquired pneumonia, Epidemiology, Europe, Incidence, Pneumococcal, Pneumococcal vaccines, Pneumonia, Streptococcus pneumoniae",

author = "Antoni Torres and Catia Cill{\'o}niz and Francesco Blasi and Chalmers, {James D.} and Jacques Gaillat and Nathalie Dartois and Heinz-Josef Schmitt and Tobias Welte",

note = "Funding for this review was provided by Pfizer Inc",

year = "2018",

month = apr,

doi = "10.1016/j.rmed.2018.02.007",

language = "English",

volume = "137",

pages = "6--13",

journal = "Respiratory Medicine",

issn = "0954-6111",

publisher = "Elsevier",

}

TY - JOUR

T1 - Burden of pneumococcal community-acquired pneumonia in adults across Europe

T2 - A literature review

AU - Torres, Antoni

AU - Cillóniz, Catia

AU - Blasi, Francesco

AU - Chalmers, James D.

AU - Gaillat, Jacques

AU - Dartois, Nathalie

AU - Schmitt, Heinz-Josef

AU - Welte, Tobias

N1 - Funding for this review was provided by Pfizer Inc

PY - 2018/4

Y1 - 2018/4

N2 - BACKGROUND: The burden of community-acquired pneumonia (CAP) caused by Streptococcus pneumoniae (pneumococcus) among adults in Europe is poorly defined.METHODS: Structured searches of PubMed were conducted to identify the incidence of pneumococcal CAP among adults across Europe.RESULTS: The overall incidence rates for CAP was 68-7000 per 100,000 and the incidence in hospitalised CAP cases of all causes was 16-3581 per 100,000. In general the incidence of CAP increased consistently with age. Available data indicated higher burdens of pneumococcal CAP caused in groups with more comorbidities. Most cases of pneumococcal CAP (30%-78%) were caused by serotypes covered by PCV13 vaccine; the incidence of PCV13-related pneumonia decreased after the introduction of childhood vaccination.CONCLUSIONS: We observed a high burden adult pneumococcal CAP in Europe despite use of the 23-valent pneumococcal polysaccharide vaccine, particularly in elderly patients with comorbidities. CAP surveillance presented wide variations across Europe. Pneumococcal CAP has to be monitored very carefully due to the possible effect of current vaccination strategies.

AB - BACKGROUND: The burden of community-acquired pneumonia (CAP) caused by Streptococcus pneumoniae (pneumococcus) among adults in Europe is poorly defined.METHODS: Structured searches of PubMed were conducted to identify the incidence of pneumococcal CAP among adults across Europe.RESULTS: The overall incidence rates for CAP was 68-7000 per 100,000 and the incidence in hospitalised CAP cases of all causes was 16-3581 per 100,000. In general the incidence of CAP increased consistently with age. Available data indicated higher burdens of pneumococcal CAP caused in groups with more comorbidities. Most cases of pneumococcal CAP (30%-78%) were caused by serotypes covered by PCV13 vaccine; the incidence of PCV13-related pneumonia decreased after the introduction of childhood vaccination.CONCLUSIONS: We observed a high burden adult pneumococcal CAP in Europe despite use of the 23-valent pneumococcal polysaccharide vaccine, particularly in elderly patients with comorbidities. CAP surveillance presented wide variations across Europe. Pneumococcal CAP has to be monitored very carefully due to the possible effect of current vaccination strategies.

KW - Community-acquired pneumonia

KW - Epidemiology

KW - Europe

KW - Incidence

KW - Pneumococcal

KW - Pneumococcal vaccines

KW - Pneumonia

KW - Streptococcus pneumoniae

U2 - 10.1016/j.rmed.2018.02.007

DO - 10.1016/j.rmed.2018.02.007

M3 - Review article

C2 - 29605214

SN - 0954-6111

VL - 137

SP - 6

EP - 13

JO - Respiratory Medicine

JF - Respiratory Medicine

ER -

Burden of pneumococcal community-acquired pneumonia in adults across Europe: A literature review

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Fingerprint

Cite this